# Medtronic (MDT) Financial Model Free Excel 3-statement financial model and company analysis for Medtronic. - Canonical: https://finamodel.com/companies/medtronic - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/MDT.xlsx ## Model Purpose This model provides a comprehensive three-statement forecast and discounted cash flow valuation to help an equity research analyst determine the intrinsic value of Medtronic plc and assess the financial impact of its ongoing portfolio restructuring and new product launches. ## Company Overview Medtronic plc is one of the world's largest medical technology, services, and solutions companies, developing devices and therapies to treat over 70 health conditions. The company operates a highly diversified, innovation-driven business model that relies heavily on continuous research and development alongside a massive global direct sales force. Business segments include: * Cardiovascular Portfolio (approximately 36% of revenue) * Neuroscience Portfolio (approximately 29% of revenue) * Medical Surgical Portfolio (approximately 26% of revenue) * Diabetes (approximately 9% of revenue) The company generates roughly half of its revenue outside the United States, making it highly sensitive to foreign exchange movements. Medtronic operates an asset-heavy manufacturing model but relies on intellectual property and clinical data for its competitive moat. Its competitive position is dominant, frequently ranking first or second in its core markets against peers like Abbott Laboratories, Boston Scientific, and Stryker. Recent major events include the divestiture of its Renal Care business into a joint venture (Mozarc Medical), the exit from the ventilator market, and significant restructuring programmes aimed at consolidating its global manufacturing and supply chain footprint. ## Revenue Deep Dive ### Cardiovascular Portfolio * **Segment name:** Cardiovascular Portfolio (comprising Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular). * **Revenue driver formula:** Prior Year Segment Revenue x (1 + Organic Volume Growth + Price/Mix Impact) + Foreign Exchange Impact. * **Historical growth rate:** 3-5% organic CAGR. * **Key growth levers and headwinds:** Adoption of pulsed field ablation (PFA) technology, leadless pacemakers (Micra), and transcatheter aortic valve replacement (TAVR) systems. Headwinds include hospital staffing shortages and pricing pressure in mature categories. * **Pricing dynamics:** Highly competitive and often subject to long-term hospital purchasing contracts and government tender pricing in international markets. * **Revenue recognition notes:** Recognised at the point of transfer of control, typically upon delivery to the hospital or when a consigned device is implanted in a patient. * **Seasonality:** The fiscal fourth quarter (ending April) is typically the strongest due to hospital capital budget exhaustion and the company's internal sales incentive structures. ### Neuroscience Portfolio * **Segment name:** Neuroscience Portfolio (comprising Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation). * **Revenue driver formula:** Prior Year Segment Revenue x (1 + Organic Volume Growth + Price/Mix Impact) + Foreign Exchange Impact. * **Historical growth rate:** 4-6% organic CAGR. * **Key growth levers and headwinds:** Driven by the AiBLE surgical ecosystem, robotic guidance systems (Mazor), and new indications for deep brain stimulation. Headwinds include the deferrable nature of certain elective spine surgeries. * **Pricing dynamics:** Capital equipment (surgical robotics) involves large upfront capital purchases or leasing arrangements, while implants are priced per procedure. * **Revenue recognition notes:** Capital equipment may include multiple performance obligations (hardware, software, maintenance), requiring revenue to be allocated and recognised over time for the service components. * **Seasonality:** Stronger in the fiscal third and fourth quarters, aligning with calendar year-end deductible resets for US patients undergoing elective procedures. ### Medical Surgical Portfolio * **Segment name:** Medical Surgical Portfolio (comprising Surgical & Endoscopy and Acute Care & Monitoring). * **Revenue driver formula:** Prior Year Segment Revenue x (1 + Organic Volume Growth + Price/Mix Impact) + Foreign Exchange Impact. * **Historical growth rate:** Flat to 2% organic CAGR. * **Key growth levers and headwinds:** Growth is driven by the Hugo robotic-assisted surgery system and advanced energy instruments. Headwinds include the strategic exit from the ventilator product line and legacy Covidien product commoditisation. * **Pricing dynamics:** High volume, lower margin consumable products face intense competitive bidding and group purchasing organisation (GPO) pricing pressure. * **Revenue recognition notes:** Primarily point-in-time recognition upon shipment of consumable supplies. * **Seasonality:** Relatively stable throughout the year, though slightly elevated in winter months due to respiratory monitoring needs. ### Diabetes * **Segment name:** Diabetes. * **Revenue driver formula:** Installed Pump Base x (Annual Consumables per User + Continuous Glucose Monitor Attachment Rate). * **Historical growth rate:** 6-10% organic CAGR (recent acceleration). * **Key growth levers and headwinds:** The rollout of the MiniMed 780G automated insulin delivery system and the Simplera continuous glucose monitor (CGM). Headwinds include intense competition from Dexcom, Abbott, and Tandem Diabetes Care. * **Pricing dynamics:** Heavily dependent on pharmacy benefit manager (PBM) formularies and Medicare/Medicaid reimbursement rates. * **Revenue recognition notes:** Pump hardware is recognised upfront, while sensors and infusion sets are recognised as recurring consumable revenue. * **Seasonality:** Strongest in the fiscal third quarter (ending January) due to US patients meeting their calendar-year health insurance deductibles. ## Cost Structure ### Variable Costs / COGS * **Line-by-line breakdown:** Direct manufacturing labour, raw materials (precious metals, electronic components, plastics), overhead allocation, freight, and royalties. * **Gross margin range:** 65.0% to 66.5% over the last 5 years. * **Key input costs and commodity exposures:** Electronic components, titanium, platinum, and global freight rates. * **How COGS scales with revenue:** Generally linear, though the company is currently executing a major supply chain consolidation programme to drive operating leverage and improve gross margins by 100-200 basis points over the medium term. ### Operating Expenses * **R&D:** Typically 8.0% to 8.8% of revenue. It covers clinical trials, regulatory submissions, and product engineering. Medtronic generally expenses R&D as incurred, though certain software development costs are capitalised. * **SG&A:** Typically 33.0% to 34.5% of revenue. This is heavily driven by the massive global direct sales force, medical education, and corporate overhead. * **Depreciation & Amortisation:** Amortisation of intangible assets (largely from the Covidien acquisition) is significant, often exceeding $1.5 billion annually. Depreciation of tangible assets runs at roughly 2.5% of revenue. * **Stock-Based Compensation:** Typically 1.0% to 1.5% of revenue. * **Restructuring / one-time charges:** Frequent. The company regularly reports restructuring charges related to its global operating model changes and facility closures. ### Margin Profile * **Gross margin:** 65.0% - 66.5%. * **EBITDA margin:** 28.0% - 30.0% (Adjusted). * **Operating margin:** 17.0% - 19.0% (GAAP), 25.0% - 26.5% (Non-GAAP). * **Net margin:** 10.0% - 12.0% (GAAP), 20.0% - 22.0% (Non-GAAP). * **Margin trend:** Gross margins have faced pressure from inflation and foreign exchange but are beginning to expand due to pricing initiatives and cost-efficiency programmes. ## Balance Sheet Structure * **Total assets:** Approximately $90 billion. * **Key asset categories:** Goodwill and intangible assets dominate the balance sheet due to a history of large acquisitions. * **Goodwill & intangibles as % of total assets:** Approximately 60% to 65%. * **Working capital profile:** * **Days Sales Outstanding (DSO):** 60 to 70 days. * **Days Inventory Outstanding (DIO):** 140 to 160 days (inventory levels are high to ensure life-saving devices are always available). * **Days Payable Outstanding (DPO):** 50 to 60 days. * **Net working capital as % of revenue:** Typically 15% to 20%. * **Is working capital positive or negative?** Positive. The company requires significant inventory and receivables to operate, meaning working capital consumes cash as the business grows. * **PP&E:** Approximately $6 billion to $7 billion, consisting of specialised manufacturing facilities, clean rooms, and surgical training centres. * **Right-of-use assets / operating leases:** Approximately $1.2 billion, primarily for office space and regional distribution centres. ## Capital Expenditure & Investment * **Capex as % of revenue:** 4.0% to 5.0%. * **Maintenance capex vs. growth capex:** Approximately 40% maintenance, 60% growth (tooling for new product lines, IT infrastructure). * **Major capex programmes underway or planned:** Consolidation of manufacturing sites and investments in automated production lines. * **Capitalised software / development costs:** Material, particularly for digital health platforms and robotic surgery software. * **M&A pattern:** Historically transformational (e.g., Covidien for $43 billion in 2015), but currently focused on aggressive bolt-on acquisitions (e.g., Affera, Intersect ENT, Epix Therapeutics) in high-growth markets. * **Typical acquisition multiple paid:** 4x to 8x forward revenue for high-growth, pre-profitability MedTech assets. ## Debt & Capital Structure * **Total debt:** Approximately $24 billion to $26 billion. * **Net debt:** Approximately $16 billion. * **Debt/EBITDA ratio:** Current net leverage is approximately 1.7x to 1.9x. * **Credit rating:** A (S&P) / A3 (Moody's). * **Key debt instruments:** Senior unsecured notes (bonds) and commercial paper for short-term liquidity. * **Maturity profile:** Well-laddered, with average maturities exceeding 8 years. * **Interest rate profile:** Predominantly fixed-rate bonds, with a weighted average interest rate of approximately 3.5% to 4.0%. * **Covenants:** Standard investment-grade covenants; no restrictive financial maintenance covenants on the public bonds. * **Share repurchase programme:** Active. The company typically repurchases $1.5 billion to $2.5 billion annually to offset dilution and return excess cash. * **Dividend policy:** Dividend aristocrat with over 45 consecutive years of increases. Payout ratio targets roughly 50% of free cash flow. ## Cash Flow Characteristics * **Operating cash flow conversion:** Strong, typically 1.0x to 1.2x of GAAP Net Income. * **Free cash flow margin:** 15.0% to 17.0% of revenue. * **Major non-cash items that bridge net income to OCF:** Amortisation of intangible assets (very large), depreciation, stock-based compensation, and deferred income taxes. * **Working capital cash flow impact:** Generally a use of cash during periods of high growth due to inventory builds for new product launches. * **Capex intensity:** Moderate (4-5% of revenue), allowing for high free cash flow generation. * **Cash tax rate vs. GAAP effective tax rate:** The non-GAAP effective tax rate is typically 14.5% to 15.5%. The cash tax rate is often lower due to R&D tax credits and the utilisation of intellectual property structures in Ireland and Switzerland. ## Sheet Structure 1. **Assumptions**: Contains all hardcoded drivers, macroeconomic inputs, tax rates, and scenario toggles. 2. **Revenue_Build**: Forecasts revenue by the four reporting segments (Cardiovascular, Neuroscience, Medical Surgical, Diabetes) with organic growth and FX impact lines for each. 3. **Income_Statement**: GAAP and Non-GAAP views, detailing COGS, R&D, SG&A, Amortisation, and Restructuring charges. 4. **Balance_Sheet**: Assets, Liabilities, and Equity, highlighting Goodwill, Intangibles, and Inventory. 5. **Cash_Flow_Statement**: Operating, Investing, and Financing cash flows, starting from GAAP Net Income. 6. **Working_Capital**: Schedules for Accounts Receivable, Inventory, and Accounts Payable based on days outstanding metrics. 7. **Debt_Schedule**: Tranches of senior notes, commercial paper, interest expense calculations, and debt paydown logic. 8. **Depreciation_Amortisation**: Waterfall schedules for PP&E depreciation and the run-off of acquisition-related intangibles. 9. **DCF_Valuation**: Unlevered free cash flow calculation, WACC build, terminal value, and implied share price. ## Key Financial Relationships 1. `Cardiovascular Revenue = Prior Year Cardiovascular Revenue * (1 + Cardiovascular Organic Growth) + Cardiovascular FX Impact` 2. `Neuroscience Revenue = Prior Year Neuroscience Revenue * (1 + Neuroscience Organic Growth) + Neuroscience FX Impact` 3. `Medical Surgical Revenue = Prior Year Medical Surgical Revenue * (1 + Medical Surgical Organic Growth) + Medical Surgical FX Impact` 4. `Diabetes Revenue = Prior Year Diabetes Revenue * (1 + Diabetes Organic Growth) + Diabetes FX Impact` 5. `Total Revenue = Cardiovascular Revenue + Neuroscience Revenue + Medical Surgical Revenue + Diabetes Revenue + Other Revenue` 6. `Cost of Products Sold = Total Revenue * (1 - Gross Margin Percentage)` 7. `R&D Expense = Total Revenue * R&D Margin Percentage` 8. `SG&A Expense = Total Revenue * SG&A Margin Percentage` 9. `Non-GAAP Operating Profit = Total Revenue - Cost of Products Sold - R&D Expense - SG&A Expense` 10. `Accounts Receivable = (Total Revenue / 365) * Days Sales Outstanding` 11. `Inventory = (Cost of Products Sold / 365) * Days Inventory Outstanding` 12. `Accounts Payable = (Cost of Products Sold / 365) * Days Payable Outstanding` 13. `Free Cash Flow = Cash from Operations - Capital Expenditures` 14. `Interest Expense = Average Total Debt Balance * Weighted Average Interest Rate` 15. `Dividends Paid = Prior Year Dividends Paid * (1 + Dividend Growth Rate)` ## Cross-Sheet Dependencies * The **Assumptions** sheet feeds all growth rates and margin profiles into the **Revenue_Build** and **Income_Statement**. * The **Revenue_Build** feeds the top line of the **Income_Statement** and drives the activity metrics in the **Working_Capital** sheet. * The **Income_Statement** generates Net Income, which is the starting point for the **Cash_Flow_Statement**. * The **Working_Capital** sheet calculates the change in net working capital, which feeds into the operating section of the **Cash_Flow_Statement**. * The **Debt_Schedule** calculates interest expense, which feeds back into the **Income_Statement** (creating a potential circular reference if interest is based on average debt, which depends on cash flow used for debt paydown). * The **Cash_Flow_Statement** determines the ending cash balance and debt requirements, which feed the **Balance_Sheet**. * The **DCF_Valuation** pulls NOPAT from the **Income_Statement**, D&A from the **Depreciation_Amortisation** sheet, Capex from the **Cash_Flow_Statement**, and changes in NWC from the **Working_Capital** sheet. ## Sign Convention * **Income Statement:** Revenue is positive. All expenses (COGS, R&D, SG&A, Interest, Taxes) are entered as positive numbers and subtracted in subtotals. * **Balance Sheet:** All assets, liabilities, and equity balances are positive. * **Cash Flow Statement:** Cash inflows are positive. Cash outflows (capital expenditures, dividends, share repurchases, debt repayment) are negative. An increase in an asset account (like inventory) is a negative cash flow. An increase in a liability account (like accounts payable) is a positive cash flow. ## Things Most Likely to Go Wrong * "Foreign currency translation can swing reported revenue by 3-5% YoY; the model must separate organic growth from FX impacts to accurately assess underlying performance." * "The company reports significant non-GAAP adjustments; failing to model the amortisation of acquisition-related intangibles will cause GAAP EPS to be wildly overstated." * "Medtronic frequently incurs restructuring charges; these should be modelled as operating expenses for GAAP purposes but added back for the non-GAAP valuation view." * "The divestiture of the Renal Care business and exit from ventilators creates a 'stub' in historical revenue; forward growth rates must be applied to the adjusted baseline, not the historical reported total." * "Inventory levels are structurally high (140+ days) due to the nature of life-saving implants; assuming standard manufacturing DIO will artificially inflate modelled free cash flow." * "The company's effective tax rate is heavily dependent on international tax jurisdictions; applying the statutory US or Irish rate will result in inaccurate net income." * "Fiscal year 2026 will contain a 53rd week; the model must account for this anomaly to prevent a false spike in modelled growth followed by a false contraction in FY27." * "Stock-based compensation is a real cost to shareholders but is excluded from management's non-GAAP EPS; the DCF must treat SBC as an expense to avoid overvaluing the equity." ## Validation Checks * "Gross margin should remain in the 65.0% to 66.5% range; flag if the model projects margins outside this historical band." * "R&D expense must remain between 8.0% and 9.0% of revenue; Medtronic cannot sustain its pipeline if R&D drops below this threshold." * "Free Cash Flow conversion (FCF / Non-GAAP Net Income) should be approximately 75% to 85%." * "Net Debt to EBITDA should remain below 2.5x to maintain the company's strong investment-grade credit rating." * "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every forecasted period." * "Dividend payout ratio should remain between 45% and 55% of free cash flow based on stated management policy." * "Days Inventory Outstanding should not fall below 130 days without a specific structural justification flagged in the model." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Cardiovascular Organic Growth | 5.0 | % | Based on FY24 actuals and FY25 guidance driven by PFA and TAVR. | | Neuroscience Organic Growth | 5.2 | % | Based on FY24 actuals and strength in Cranial & Spinal Technologies. | | Medical Surgical Organic Growth | 1.0 | % | Based on FY24 actuals, reflecting legacy product headwinds. | | Diabetes Organic Growth | 8.6 | % | Based on FY24 actuals and the MiniMed 780G rollout. | | Gross Margin | 65.8 | % | Blended average of recent historical performance and management efficiency targets. | | R&D as % of Revenue | 8.6 | % | Consistent with FY24 actuals and historical averages. | | SG&A as % of Revenue | 33.5 | % | Reflects ongoing cost-reduction programmes offsetting wage inflation. | | Days Sales Outstanding (DSO) | 65 | Days | Historical average based on hospital payment cycles. | | Days Inventory Outstanding (DIO) | 150 | Days | Historical average required to support global medical device distribution. | | Days Payable Outstanding (DPO) | 55 | Days | Historical average based on supplier terms. | | Capex as % of Revenue | 4.5 | % | Management guidance for maintenance and growth capital requirements. | | Effective Tax Rate (Non-GAAP) | 15.0 | % | Based on FY24 actuals and management guidance for FY25. | | Dividend per Share | 2.76 | $ | Actual FY24 dividend payout. | | Share Repurchases | 1,600 | $ Millions | Based on FY24 actuals and management's capital return commitments. | | Weighted Average Cost of Capital | 7.5 | % | Based on current risk-free rates, equity risk premium, and MDT's low beta. | | Terminal Growth Rate | 2.5 | % | Aligns with long-term global healthcare spending growth. | ## Data Sources & Benchmarks * **SEC Filings:** Medtronic Investor Relations website and SEC EDGAR (Form 10-K, 10-Q, 8-K). * **Key Peers for Benchmarking:** Abbott Laboratories (ABT), Boston Scientific (BSX), Stryker (SYK), Johnson & Johnson (JNJ - MedTech division). * **Industry Data Sources:** Evaluate MedTech (for market share data), IQVIA (for procedure volume trends), and CMS (for Medicare reimbursement rate changes). * **Consensus Estimates:** Bloomberg or FactSet for near-term revenue and EPS consensus to validate model outputs. ## Sources * Medtronic plc FY24 Annual Report (Form 10-K) * Medtronic Q3 FY25 Earnings Presentation (February 18, 2025) * Medtronic Q3 FY25 Press Release (February 18, 2025) * Medtronic FY24 Earnings Press Release (May 23, 2024) * Medtronic Investor Relations Website (investorrelations.medtronic.com) --- ## Frequently asked questions ### What kind of company is Medtronic and what does it do? Medtronic plc is one of the world's largest medical technology, services, and solutions companies, developing devices and therapies to treat over 70 health conditions. It operates a highly diversified, innovation-driven business model that relies heavily on continuous research and development. ### What are Medtronic's primary revenue sources and how diversified is its business? Medtronic generates revenue primarily from its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios. Roughly half of its revenue comes from outside the United States, making its financial performance sensitive to foreign exchange movements. ### What are the key assumptions for Medtronic's financial model regarding capital expenditures? The financial model assumes Medtronic's capital expenditure (Capex) as a percentage of revenue is 4.279%. This capex is approximately 40% maintenance and 60% growth, focused on consolidating manufacturing sites and investing in automated production lines. ### What is the purpose of the Medtronic financial model and its valuation approach? This model provides a comprehensive three-statement forecast and discounted cash flow valuation to help determine the intrinsic value of Medtronic plc. It also assists in assessing the financial impact of the company's ongoing portfolio restructuring and new product launches. ### Can I download an Excel financial model for Medtronic (MDT) and what is its forecast horizon? Yes, a downloadable Excel financial model for Medtronic (MDT) is available. This model provides a forecast horizon covering fiscal years 2026 through 2030. ### How does Medtronic's balance sheet structure reflect its business strategy? Medtronic's balance sheet is dominated by goodwill and intangible assets, which comprise approximately 60% to 65% of total assets, reflecting its history of large acquisitions. The company also maintains high inventory levels, resulting in positive net working capital that consumes cash as the business grows. [Interactive forecast calculator](https://finamodel.com/companies/medtronic/forecast)